| First Author | Lamarche É | Year | 2021 |
| Journal | Development | Volume | 148 |
| Issue | 3 | PubMed ID | 33462116 |
| Mgi Jnum | J:302545 | Mgi Id | MGI:6507918 |
| Doi | 10.1242/dev.195495 | Citation | Lamarche E, et al. (2021) SMAD2 promotes myogenin expression and terminal myogenic differentiation. Development 148(3):dev195495 |
| abstractText | SMAD2 is a transcription factor, the activity of which is regulated by members of the transforming growth factor beta (TGFbeta) superfamily. Although activation of SMAD2 and SMAD3 downstream of TGFbeta or myostatin signaling is known to inhibit myogenesis, we found that SMAD2 in the absence of TGFbeta signaling promotes terminal myogenic differentiation. We found that, during myogenic differentiation, SMAD2 expression is induced. Knockout of SMAD2 expression in primary myoblasts did not affect the efficiency of myogenic differentiation but produced smaller myotubes with reduced expression of the terminal differentiation marker myogenin. Conversely, overexpression of SMAD2 stimulated myogenin expression, and enhanced both differentiation and fusion, and these effects were independent of classical activation by the TGFbeta receptor complex. Loss of Smad2 in muscle satellite cells in vivo resulted in decreased muscle fiber caliber and impaired regeneration after acute injury. Taken together, we demonstrate that SMAD2 is an important positive regulator of myogenic differentiation, in part through the regulation of Myog. |
